GeoVax Labs Inc. To Present At The LD Micro Invitational Conference

ATLANTA, GA--(Marketwired - May 27, 2015) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the LD Micro Invitational Conference on June 1, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company’s presentation by Dr. Robert T. McNally, President and CEO, is scheduled to begin at 2:00PM PDT. Management will also be available during the conference for one-on-one meetings.

About LD Micro
LD Micro is an internet-based investment newsletter firm that focuses on undervalued companies in the micro-cap space. It is a non-registered investment advisor. LD Micro hosts the LD Micro “Invitational” and “Main Event” Conferences for investors in June and December of each year, respectively. Last year’s Invitational Conference had over 700 investors attend, including institutional interest from fund managers, analysts and traders representing over 165 firms.

About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our novel vaccine platform. Our current development programs are focused on vaccines against Ebola and Marburg viruses, and Human Immunodeficiency Virus (HIV). We believe our technology and vaccine development expertise is well-suited for a wide variety of human infectious diseases for which there is an unmet medical need, and we intend to pursue expansion of our product pipeline as resources permit. Our vaccine platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Producing non-infectious virus-like particles in the person being vaccinated circumvents the need to purify virus-like particles for inoculation. The production of virus-like particles in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear. Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID), part of the U.S. National Institutes of Health (NIH). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in 500 humans. For more information, go to www.geovax.com.

Forward-Looking Statements
Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax’s filings with the Securities and Exchange Commission including those set forth at “Risk Factors” in GeoVax’s Form 10-K.